

Financial news for KMDA dated on 2020-05-27: 96 Biggest Movers From Yesterday

Financial news for KMDA dated on 2020-05-26: 61 Stocks Moving In Tuesday's Mid-Day Session

Financial news for KMDA dated on 2020-05-22: Stocks That Hit 52-Week Highs On Friday

Financial news for KMDA dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for KMDA dated on 2020-05-22: 64 Biggest Movers From Yesterday

Financial news for KMDA dated on 2020-05-18: Kamada shares are trading lower despite the company reporting better-than-expected Q1 earnings results.

Financial news for KMDA dated on 2020-05-18: Recap: Kamada Q1 Earnings

Financial news for KMDA dated on 2020-05-18: Kamada Q1 EPS \$0.12 Beats \$0.06 Estimate, Sales \$33.290M Beat \$30.120M Estimate

Financial news for KMDA dated on 2020-05-18: Earnings Scheduled For May 18, 2020

Financial news for KMDA dated on 2020-04-27: Kamada And Kedrion Biopharma Announce Global Collaboration For Development, Manufacturing And Distribution Of A Plasma-Derived Anti-SARS-CoV-2 (Coronavirus COVID-19) Polyclonal Immunoglobulin Product

Financial news for KMDA dated on 2020-03-23: 36 Stocks Moving in Monday's Pre-Market Session

Financial news for KMDA dated on 2020-03-19: Kamada Shares On Watch; Co. On Mar. 11 Announced It Plans To Utilize Hyper-Immunoglobulin Technology As A Potential Coronavirus Treatment

Financial news for KMDA dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for KMDA dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for KMDA dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for KMDA dated on 2020-03-11: Kamada Says Plans To Initiate Development Of Anti-Coronavirus Polyclonal Immunoglobulin

Financial news for KMDA dated on 2020-02-12: Kamada Q4 EPS \$0.13, Inline, Sales \$32.071M Miss \$33.04M Estimate

Financial news for KMDA dated on 2020-01-21: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for KMDA dated on 2020-01-21: Kamada Announces \$25M Private Placement With FIMI Opportunity Fund; Co. To Issue ~4.17M Shares To FIMI At \$6/Share

Financial news for KMDA dated on 2020-01-07: Kamada Sees Prelim. Q4 Sales \$31.4M-\$32.4M vs \$35.4M Est., FY19 Sales \$126.5M-\$127.5M vs \$130.47M Est.; Sees FY20 Sales \$132M-\$137M vs \$121.51M Est.

Financial news for KMDA dated on 2019-12-16: Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovaAate Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

Financial news for KMDA dated on 2019-12-09: Kamada Wins a 12 Year Supply Contract Which is Expected to Add \$8-\$10M of Annual Revenue

Financial news for KMDA dated on 2019-12-02: Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel, Expects Revenue of \$20-\$30M Within Several Years of Launch

Financial news for KMDA dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for KMDA dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for KMDA dated on 2019-11-25: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for KMDA dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for KMDA dated on 2019-11-25: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for KMDA dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for KMDA dated on 2019-11-22: 66 Biggest Movers From Yesterday

Financial news for KMDA dated on 2019-11-13: Kamada Reaffirms FY19 Sales Guidance Of \$125M-\$130M vs \$128.91M Est.

Financial news for KMDA dated on 2019-11-13: Kamada Q3 EPS \$0.14 Beats \$0.07 Estimate, Sales \$33.1M Beat \$28.92M Estimate

Financial news for KMDA dated on 2019-10-29: Kamada and Kedrion Biopharma Highlights Publication Of Results From Registration Study Of KEDRAB In Human Vaccines & Immunotherapeutics Medical Journal

Financial news for KMDA dated on 2019-09-03: Kamada Announces Extension Of GLASSIA Supply Agreement With Takeda

Financial news for KMDA dated on 2019-08-08: Kamada Earlier Reported Talks With Takeda Related To Potential Extension Of Period For Transition Of GLASSIA Manufacturing To Takeda

Financial news for KMDA dated on 2019-08-06: Kamada Q2 EPS \$0.15 Beats \$0.14 Estimate, Sales \$35.3M Beat \$34.37M Estimate

Financial news for KMDA dated on 2019-06-28: Cannabics Pharmaceuticals Gets New Directors

Financial news for KMDA dated on 2019-05-14: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KMDA dated on 2019-05-14: Earnings Scheduled For May 14, 2019

Financial news for KMDA dated on 2019-05-13: A Preview Of Kamada's Q1 Earnings

Financial news for KMDA dated on 2019-04-16: Kamada Shares Resume Trade

Financial news for KMDA dated on 2019-04-16: Kamada Ltd. Shares To Resume Trade At 7:30 a.m. EDT

Financial news for KMDA dated on 2019-04-16: Kamada announces FDA Acceptance Of Inhaled AAT Program Path Forward

Financial news for KMDA dated on 2019-04-16: Kamada Shares Halted, News Pending

Financial news for KMDA dated on 2019-02-12: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KMDA dated on 2019-02-12: Kamada Reports Q4 EPS Of \$0.44 May Not Compare To \$0.18 Estimate, Sales \$48.2M Beat \$41.37M Est.; Reiterates FY19 Revenue Guidance Of \$125M-130M vs \$127.82M Est.

Financial news for KMDA dated on 2019-02-12: Earnings Scheduled For February 12, 2019

Financial news for KMDA dated on 2019-02-06: UPDATE: Kamada Sees Top-Line Results For Phase 2 Intravenous Alpha-1 Antitrypsin Trial In 2H'2019

Financial news for KMDA dated on 2019-02-06: UPDATE: Kamada Reports 'IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test'

Financial news for KMDA dated on 2019-02-06: Kamada Reports Added Interim Results From Phase 2 Proof-Of-Concept Trial Of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Financial news for KMDA dated on 2019-01-02: Kamada Reaffirms FY19 Sales Guidance Of \$125M-\$130M vs \$127.82M Est.

Financial news for KMDA dated on 2019-01-02: Kamada Sees Q4 Sales \$46.7M-\$48.7M vs \$39.37M Est. FY18 Sales \$113M-\$115M vs \$105.88M Est.

Financial news for KMDA dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for KMDA dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for KMDA dated on 2018-11-12: Kamada Ltd. Q3 EPS \$(0.06) Misses \$(0.01) Estimate, Sales \$14.975M Miss \$18.13M Estimate

Financial news for KMDA dated on 2018-11-12: Earnings Scheduled For November 12, 2018

Financial news for KMDA dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for KMDA dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for KMDA dated on 2018-09-14: The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut

Financial news for KMDA dated on 2018-09-05: Kamada Announces Extension Of Collaboration With Massachusetts General Hospital For Proof-Of-Concept Study Evaluating Potential Benefit Of Liquid Alpha-1 Antitrypsin On Liver Preservation Prior To Transplantation

Financial news for KMDA dated on 2018-08-29: Kamada Cuts FY18 Sales Guidance From \$116M-\$120M To \$102M-\$108M; Co. Says Cut Is Due To Delayed Planned Product Shipments As A Result Of Recently Settled Labor Strike

Financial news for KMDA dated on 2018-08-07: Kamada Is Unable To Reaffirm 2018 Revenue Guidance Due To Ongoing Labor Strike At Co.'s Production Facility

Financial news for KMDA dated on 2018-08-07: Kamada Q2 EPS \$0.14 Beats \$0.09 Estimate, Sales \$33.8M Beat \$30.6M Estimate

Financial news for KMDA dated on 2018-07-23: Stocks Which Set New 52-Week Highs Friday

Financial news for KMDA dated on 2018-07-10: Kamada Receives Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT, Co. Plans to Submit Clinical Trial Application; Intends to Engage in Commercialization Discussions for A Strategic European Partner

Financial news for KMDA dated on 2018-05-15: Kamada Sees FY18 Sales \$116-\$120M vs \$120.6M Est.

Financial news for KMDA dated on 2018-05-15: Kamada Ltd. - Ordinary Shares Q1 EPS \$0.03 Beats \$0.02 Estimate, Sales \$17.441M Miss \$24.02M Estimate

Financial news for KMDA dated on 2018-05-15: Earnings Scheduled For May 15, 2018

Financial news for KMDA dated on 2018-05-08: Kamada, Kedrion Biopharma Report LAUNCH Of KEDRAB Rabies Immune Globulin In US, Initial Shipments Are Now Reaching Healthcare Practitioners

Financial news for KMDA dated on 2018-04-23: Kamada Reports that the FDA Has Continued Safety Concerns for AAT, Kamada No Longer Expects to Initiate its Phase 3 Trial in 2H 2018

Financial news for KMDA dated on 2018-04-23: Kamada Halted, News Pending

Financial news for KMDA dated on 2018-02-07: Kamada Reports Q4 EPS \$0.16 vs \$0.08 Est., Sales \$35.7M vs \$33.0M Est.

Financial news for KMDA dated on 2018-02-02: Benzinga's Top Upgrades, Downgrades For February 2, 2018

Financial news for KMDA dated on 2018-02-02: Chardan Capital Initiates Coverage On Kamada with Buy Rating, Announces \$7.00 Price Target

Financial news for KMDA dated on 2018-01-08: Kamada Shares Up 1% On Light Volume; Co. Earlier Offered Interim Results From Phase 2 Trial Of IV Alpha-1 Antitrypsin Treatment, Showed 'Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment'

Financial news for KMDA dated on 2018-01-04: Kamada Reports Collaboration With Consortium Of Prominent Hospitals For Evaluation Of Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

Financial news for KMDA dated on 2017-11-21: Kamada Wins \$13M 3 Year Supply Agreement from KamRAB

Financial news for KMDA dated on 2017-11-20: Kamada and Chiesi Farmaceutici Mutually Agree to Terminate Their European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

Financial news for KMDA dated on 2017-11-13: Kamada Sees FY18 Sales \$116M to \$120M vs \$121M Est.

Financial news for KMDA dated on 2017-11-13: Kamada Reaffirms FY 2017 Guidance

Financial news for KMDA dated on 2017-11-13: UPDATE: Kamada Reports Q3 Adj. EPS \$(0.00) vs \$0.02 Est., Sales \$22.9M vs \$25.0M Est.

Financial news for KMDA dated on 2017-11-13: Earnings Scheduled For November 13, 2017

Financial news for KMDA dated on 2017-11-01: UPDATE: Kamada On Phase 2 Results Of Alpha-1 Antitrypsin: 'Efficacy trend was demonstrated in the pre-determined sub group of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg'

Financial news for KMDA dated on 2017-11-01: Kamada 8-K Shows Top-Line Results From Phase 2 Trial Of Alpha-1 Antitrypsin For Newly-Diagnosed Type-1 Diabetes Patients: 'No significant treatment effect was observed in the overall study population'

Financial news for KMDA dated on 2017-10-26: Secondary Offering Lockup Expirations Today For Kamada and Actinium Pharma

Financial news for KMDA dated on 2017-10-23: The Week Ahead: Earnings Season Starts In Earnest

Financial news for KMDA dated on 2017-10-18: 13 Stocks Moving In Wednesday's After-Hours Session

Financial news for KMDA dated on 2017-09-18: Kamada CEO and CFO to Step Down, Announces Chaime Orlev CFO

Financial news for KMDA dated on 2017-09-13: 13D Filing Shows Brosh Capital Reporting 4.7% Stake In Kamada

Financial news for KMDA dated on 2017-08-28: FDA Issued Letter to Kamada Stating that it Continues to have Concerns and Questions about Safety and Efficacy of Inhaled AAT -6K

Financial news for KMDA dated on 2017-08-25: 18 Biggest Mid-Day Gainers For Friday

Financial news for KMDA dated on 2017-08-25: Mid-Morning Market Update: Markets Open Higher; Big Lots Profit Tops Estimates

Financial news for KMDA dated on 2017-08-25: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for KMDA dated on 2017-08-25: Kamada Shares Resume, Now Up 23%

Financial news for KMDA dated on 2017-08-25: Kedrion Biopharma, Kamada Report Received FDA Approval Of KEDRAB For Post-Exposure Prophylaxis Against Rabies Infection

Financial news for KMDA dated on 2017-08-25: Kamada Halted News Pending

Financial news for KMDA dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for KMDA dated on 2017-08-01: Kamada Q2 EPS \$0.13 vs \$0.12 Est., Sales \$32.5M vs \$33.2M Est.

Financial news for KMDA dated on 2017-07-28: 20 Biggest Mid-Day Losers For Friday

Financial news for KMDA dated on 2017-07-28: Kamada Prices ~3.33M Share Common Stock Offering At \$4.50/Share

Financial news for KMDA dated on 2017-07-27: Kamada Pre-Announces Q2 Sales Of \$32.5M vs \$33.1M Est.

Financial news for KMDA dated on 2017-07-20: Kamada Reports Submission Of Proposed Phase 3 Protocol To FDA For Inhaled Alpha-1 Antitrypsin For Treatment Of Alpha-1 Antitrypsin Deficiency Disease

Financial news for KMDA dated on 2017-07-13: Kamada Files to Offer Up to \$100M in Shares -F3

Financial news for KMDA dated on 2017-06-22: Mid-Afternoon Market Update: Steelcase

Tumbles Following Disappointing Earnings Report; Staples Shares Surge

Financial news for KMDA dated on 2017-06-22: 11 Biggest Mid-Day Losers For Thursday

Financial news for KMDA dated on 2017-06-22: Mid-Day Market Update: Oracle Surges On Earnings Beat; Kamada Shares Plummet

Financial news for KMDA dated on 2017-06-22: Mid-Morning Market Update: Markets Mostly Flat; Accenture Posts In-Line Q3 Earnings

Financial news for KMDA dated on 2017-06-22: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for KMDA dated on 2017-06-22: Kamada Shares Resume, Now Down 20%

Financial news for KMDA dated on 2017-06-22: Kamada Shares To Resume Trade At 7:30 a.m. EDT

Financial news for KMDA dated on 2017-06-22: Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin

Financial news for KMDA dated on 2017-06-22: Kamada Halted, News Pending

Financial news for KMDA dated on 2017-06-12: Kamada Announces Milestone Payment from Shire for GLASSIA

Financial news for KMDA dated on 2017-06-07: 15 Biggest Mid-Day Losers For Wednesday

Financial news for KMDA dated on 2017-06-07: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for KMDA dated on 2017-06-05: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for KMDA dated on 2017-06-01: 18 Biggest Mid-Day Gainers For Thursday

Financial news for KMDA dated on 2017-05-24: Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 AATD Conference

Financial news for KMDA dated on 2017-05-16: Kamada Sees FY 2017 Sales \$100M vs \$101M Est

Financial news for KMDA dated on 2017-05-16: Kamada Q1 EPS \$(0.11) vs \$(0.03) Est, Sales \$11.6M vs \$20.77M Est

Financial news for KMDA dated on 2017-02-21: Kamada Announces Collaboration with Massachusetts General Hospital for Proof of Concept Study Evaluating Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

Financial news for KMDA dated on 2017-02-06: Kamada Q4 EPS \$(0.05) vs \$0.01 Est, Revenue \$77.49M

Financial news for KMDA dated on 2016-11-10: Kamada Reports Q3 EPS \$(0.14) vs. Est. \$(0.07), Rev. \$19.4M vs. Est. \$19.8M

Financial news for KMDA dated on 2016-11-07: Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment, Has PDUFA Goal Date Of Aug. 29th 2017

Financial news for KMDA dated on 2016-11-01: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KMDA dated on 2016-10-06: 12 Biggest Mid-Day Gainers For Thursday

Financial news for KMDA dated on 2016-10-06: Stocks Hitting 52-Week Highs

Financial news for KMDA dated on 2016-10-06: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for KMDA dated on 2016-10-06: Kamada Reports Extension of GLASSIA Supply, Distribution Deal with Shire, Has Minimum of \$237M in Sales Over FY17-FY20

Financial news for KMDA dated on 2016-09-01: H.C. Wainwright Talks Kamada's Recent Phase 2 Results

Financial news for KMDA dated on 2016-09-01: Kamada and Kedrion Submit Biological License Application With FDA For Rabies Treatment

Financial news for KMDA dated on 2016-08-30: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for KMDA dated on 2016-08-30: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KMDA dated on 2016-08-30: A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Consumer Confidence Report

Financial news for KMDA dated on 2016-08-30: Kamada's Phase 2 Trial On Inhaled Alpha-1 Antitrypsin Meets Primary Endpoint

Financial news for KMDA dated on 2016-08-30: Kamada Says Meets Primary Endpoint Of U.S. Phase 2 Study Of Inhaled Alpha-1 Antitrypsin for Treatment Of Alpha-1 Antitrypsin Deficiency

Financial news for KMDA dated on 2016-08-02: Kamada Sees FY 2016 Revenue \$75M to \$80M vs \$78.5M est

Financial news for KMDA dated on 2016-08-02: Kamada Q2 EPS (\$0.04) vs (\$0.04) est, Revenue \$19.1M vs \$18.5M est

Financial news for KMDA dated on 2016-05-25: Kamada Reports Collaboration to Provide Early Access Throughout Europe to Alpha-1 Antitrypsin to Treat Bone Marrow Transplant Patients

Financial news for KMDA dated on 2016-05-09: Kamada Q1 EPS (\$0.06) vs (\$0.06) est, Revenue \$14.8M vs \$15.1M est

Financial news for KMDA dated on 2016-05-02: Kamada Reports Received Two Milestone Payments Under Strategic Deals with Chiesi Farmaceutici, Baxalta

Financial news for KMDA dated on 2016-04-06: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin

Financial news for KMDA dated on 2016-03-28: Kamada Submits Marketing Application to Europe For Alpha-1 Antitrypsin Deficiency

Financial news for KMDA dated on 2015-12-23: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as Post-Exposure Treatment

Financial news for KMDA dated on 2015-11-10: Kamada Reports Q3 (\$0.13) Vs (\$0.04)

Financial news for KMDA dated on 2015-11-10: Kamada Sees FY15 Rev. \$70-\$73M vs. Est. \$72.21M

Financial news for KMDA dated on 2015-11-10: Kamada Reports Q3 EPS \$(0.13) vs. Est. \$(0.04), Rev. \$16.069M vs. Est. \$18.67M

Financial news for KMDA dated on 2015-10-16: Kamada Reports Third Extension of Strategic Agreement with Baxalta

Financial news for KMDA dated on 2015-07-08: Kamada Affirms Revenue Projection For The First Half of 2015 At \$28M; As A Result, Affirms FY15 Guidance

Financial news for KMDA dated on 2015-07-01: Kamada Awarded Key New Patent for Inhaled AAT, eFlow Nebulizer System in Israel

Financial news for KMDA dated on 2015-05-20: Kamada Announces Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency

Financial news for KMDA dated on 2015-05-12: Kamada Posts Q1 Loss

Financial news for KMDA dated on 2015-05-12: Kamada Reports Q1 Loss \$0.15 Vs Exp \$0.03, Revs \$8.93 Vs \$16.12M

Financial news for KMDA dated on 2015-05-12: Earnings Scheduled For May 12, 2015

Financial news for KMDA dated on 2015-04-20: Kamada Announces Additional Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat AAT Deficiency

Financial news for KMDA dated on 2015-03-23: Morning Market Gainers

Financial news for KMDA dated on 2015-03-23: Benzinga's Top #PreMarket Gainers

Financial news for KMDA dated on 2015-03-23: Kamada Announces European Orphan Drug Designation for Its Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease

Financial news for KMDA dated on 2015-03-11: Kamada Announces Eran Schenker VP, Medical Director

Financial news for KMDA dated on 2015-02-02: Morning Market Gainers

Financial news for KMDA dated on 2015-02-02: Benzinga's Top #PreMarket Gainers

Financial news for KMDA dated on 2015-01-07: Kamada Announces Update For Phase 2 and 3 Trial, Says Encouraged

Financial news for KMDA dated on 2014-11-12: Stocks Hitting 52-Week Lows

Financial news for KMDA dated on 2014-11-12: Morning Market Losers

Financial news for KMDA dated on 2014-11-12: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-11-12: Earnings Scheduled For November 12, 2014

Financial news for KMDA dated on 2014-10-29: FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease

Financial news for KMDA dated on 2014-10-14: Stocks Hitting 52-Week Lows

Financial news for KMDA dated on 2014-09-29: Kamada Extends Strategic Agreement with Baxter

Financial news for KMDA dated on 2014-09-09: Morning Market Losers

Financial news for KMDA dated on 2014-09-09: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-09-08: Stocks Hitting 52-Week Lows

Financial news for KMDA dated on 2014-09-08: Morning Market Losers

Financial news for KMDA dated on 2014-09-08: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-09-04: Midday Losers From Thursday, September 4

Financial news for KMDA dated on 2014-09-04: Stocks Hitting 52-Week Lows

Financial news for KMDA dated on 2014-09-04: Morning Market Losers

Financial news for KMDA dated on 2014-09-04: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-09-04: Shares Of Kamada Down Over 20%

Financial news for KMDA dated on 2014-09-04: Kamada Resumes Trading Down over 4%

Financial news for KMDA dated on 2014-09-04: Kamada Shares To Resume Trading At 07:30AM EDT

Financial news for KMDA dated on 2014-09-04: UPDATE: Kamada to Discuss With FDA US Path for Registration; Continues With Plans for EMA Submission

Financial news for KMDA dated on 2014-09-04: UPDATE: Kamada Says First AAT Deficiency Treatment to Show Impact on Lung Function

Financial news for KMDA dated on 2014-09-04: PREVIEW: Kamada to Resume Trading at 7:30AM ET

Financial news for KMDA dated on 2014-09-04: Kamada Says Did Not Achieve Primary Endpoints For Phase 2 And 3 For Alpha-1 Antitrypsin

Financial news for KMDA dated on 2014-09-04: Kamada Halted

Financial news for KMDA dated on 2014-09-03: Kamada to Announce results From Phase 2/3 Trials of Inhaled AAT

Financial news for KMDA dated on 2014-08-14: Kamada Ltd. Reports Q2 EPS of \$(0.23) vs \$(0.02) Est; Revenue of \$15.80M vs \$17.17M Est

Financial news for KMDA dated on 2014-06-26: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-06-24: Stocks Hitting 52-Week Lows

Financial news for KMDA dated on 2014-06-23: Stocks Hitting 52-Week Lows

Financial news for KMDA dated on 2014-05-21: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-05-19: Morning Market Losers

Financial news for KMDA dated on 2014-05-19: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-05-16: Stocks Hitting 52-Week Lows

Financial news for KMDA dated on 2014-05-16: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-05-15: Kamada to Announce Results from Phase 2/3 Clinical Trial of Inhaled AAT to Treat AATD on May 16

Financial news for KMDA dated on 2014-04-24: Kamada Announces Significantly Improved Infusion Rate for Glassia

Financial news for KMDA dated on 2014-04-03: Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

Financial news for KMDA dated on 2014-04-03: Morning Market Movers

Financial news for KMDA dated on 2014-04-03: Kamada Announces US POC Study with Glassia to Treat GVHD

Financial news for KMDA dated on 2014-03-24: Kamada Initiates Phase 2 US Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency

Financial news for KMDA dated on 2014-03-21: Kamada to Report Top-Line Data from Phase 2/3 Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency by Late April or Early May

Financial news for KMDA dated on 2014-03-06: Benzinga's Top #PreMarket Losers

Financial news for KMDA dated on 2014-02-05: Kamada Reports Q4 EPS of \$0.04 vs \$0.05 Est; Revenue of \$24.40M vs \$25.22M Est

Financial news for KMDA dated on 2013-08-01: Kamada Ltd. Reports Q2 EPS of \$0.03 vs \$0.01 Est; Revenue of \$16.10M vs \$16.30M Est

Financial news for KMDA dated on 2013-06-25: UPDATE: Jefferies Initiates Kamada at Buy on Solid Foundation

Financial news for KMDA dated on 2013-06-25: UPDATE: Oppenheimer Initiates Kamada at Outperform on Pioneering Inhaled Delivery with AAT Treatment

Financial news for KMDA dated on 2013-06-25: Jefferies Initiates Coverage on Kamada Ltd. at Buy, Announces \$15.00 PT

Financial news for KMDA dated on 2013-06-25: Benzinga's Top Initiations

Financial news for KMDA dated on 2013-06-25: Morgan Stanley Initiates Coverage on Kamada Ltd. at Equal-weight

Financial news for KMDA dated on 2013-06-25: Oppenheimer Initiates Coverage on Kamada Ltd. at Outperform, Announces \$14.00 PT

Financial news for KMDA dated on 2013-06-24: Kamada Granted Two Key Patents

Financial news for KMDA dated on 2013-05-31: Shares of Kamada Open for Trade at \$9.71/Share After Pricing at \$9.25

Financial news for KMDA dated on 2013-05-31: Shares of Kamada to Open for Quote at 10:45AM EDT, to Open for Trade at 11AM

Financial news for KMDA dated on 2013-05-31: Kamada Ltd. Prices 5.58M shares at \$9.25/Share, Stock Will Begin Trading Today